Arctic Bioscience AS (DE:9TD) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Arctic Bioscience AS has presented promising research on the anti-psoriatic effects of phospholipid esters from herring roe oil, providing insights into the mode-of-action of their investigational drug HRO350. These findings, which were showcased at the EADV congress in Amsterdam, support the ongoing phase 2b HeROPA clinical trial for mild-to-moderate psoriasis, with results expected by late 2024. The company, known for its marine compound-based pharmaceutical and nutraceutical products, continues to advance in its clinical development program with the support of the Research Council of Norway.
For further insights into DE:9TD stock, check out TipRanks’ Stock Analysis page.
